# Rollover Study From EXG-US-01

> **NCT05868499** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Elixirgen Therapeutics, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Telomere Biology Disorders With Bone Marrow Failure

## Interventions

- **BIOLOGICAL:** EXG34217

## Key facts

- **NCT ID:** NCT05868499
- **Lead sponsor:** Elixirgen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-01-01
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05868499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05868499, "Rollover Study From EXG-US-01". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05868499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*